Recursion releases open-source data from largest ever dataset of biological images and a machine learning competition available through NeurIPS 2019. Recursion Releases Open-Source Data from ...

One outcome of the big data efforts is a new, publicly available data set that Recursion released in May, called the RxRx1. It consists of 300 gigabytes of over 100,000 images "representing ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to ...

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding ...

By generating these ever-growing phenomics data alongside algorithms enabling their relatability across experiments, time and disease modality, Recursion is building functional maps of human biology.

Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...

Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify ...